Ocedurenone

Ocedurenone, formerly known as KBP-5074, is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments. In 2023, KPB Biosciences entered in talks to sell the drug to Novo Nordisk for USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.